Holen Sie sich die Stockscreener-App
15.40
2.90%
-0.46
Schlusskurs vom Vortag:
$15.86
Offen:
$15.75
24-Stunden-Volumen:
1.46M
Relative Volume:
1.03
Marktkapitalisierung:
$1.50B
Einnahmen:
$221.08M
Nettoeinkommen (Verlust:
$-2.92M
KGV:
308.00
EPS:
0.05
Netto-Cashflow:
$5.89M
1W Leistung:
-2.28%
1M Leistung:
+14.93%
6M Leistung:
+93.47%
1J Leistung:
+10.43%
1-Tages-Spanne:
$15.37
$15.81
1-Wochen-Bereich:
$15.00
$16.04
52-Wochen-Spanne:
$6.38
$16.66
Avadel Pharmaceuticals Plc Stock (AVDL) Company Profile
Firmenname
Avadel Pharmaceuticals Plc
Sektor
Telefon
636-449-1830
Adresse
BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK, DUBLIN
Vergleichen Sie AVDL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVDL
Avadel Pharmaceuticals Plc
|
15.40 | 1.54B | 221.08M | -2.92M | 5.89M | 0.05 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Avadel Pharmaceuticals Plc Stock (AVDL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Eingeleitet | Wells Fargo | Equal Weight |
| 2025-07-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-06-12 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-03-05 | Bestätigt | H.C. Wainwright | Buy |
| 2024-03-05 | Bestätigt | Needham | Buy |
| 2024-03-05 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2022-11-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-28 | Fortgesetzt | Craig Hallum | Buy |
| 2022-05-26 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2020-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2020-07-21 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-03 | Eingeleitet | Jefferies | Buy |
| 2020-03-12 | Eingeleitet | Stifel | Buy |
| 2020-02-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-01-30 | Eingeleitet | Craig Hallum | Buy |
| 2019-06-14 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-02-08 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
Alle ansehen
Avadel Pharmaceuticals Plc Aktie (AVDL) Neueste Nachrichten
150,451 Shares in Avadel Pharmaceuticals PLC. $AVDL Acquired by Cubist Systematic Strategies LLC - MarketBeat
HC Wainwright Brokers Lift Earnings Estimates for AVDL - MarketBeat
Avadel: LUMRYZ Momentum And Pipeline Expansion Support Buy Rating - Seeking Alpha
Avadel Pharmaceuticals PLC. $AVDL Position Lifted by Two Seas Capital LP - MarketBeat
Invenomic Capital Management LP Takes Position in Avadel Pharmaceuticals PLC. $AVDL - MarketBeat
Trexquant Investment LP Buys New Holdings in Avadel Pharmaceuticals PLC. $AVDL - MarketBeat
Analysts Set Expectations for AVDL Q3 Earnings - MarketBeat
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
165,520 Stock Options: Avadel Pharmaceuticals Grants Major Inducement Awards to New Key Hires - Stock Titan
Russell Investments Group Ltd. Reduces Stock Holdings in Avadel Pharmaceuticals PLC. $AVDL - MarketBeat
Avadel Pharmaceuticals (NASDAQ:AVDL) Given New $36.00 Price Target at HC Wainwright - MarketBeat
What is Lifesci Capital's Estimate for AVDL Q2 Earnings? - MarketBeat
What is the earnings history of Avadel Pharmaceuticals plcMarket Volume Summary & Safe Entry Trade Reports - Lancaster City Council
Lifesci Capital Upgrades Avadel Pharmaceuticals (NASDAQ:AVDL) to Strong-Buy - MarketBeat
Avadel (AVDL) Licenses Valiloxybate and Unveils LUMRYZ Data at World Sleep 2025 - Yahoo Finance
Avadel Pharmaceuticals (NASDAQ:AVDL) Shares Gap DownHere's What Happened - MarketBeat
Is Avadel Pharmaceuticals plc currently under institutional pressure2025 Buyback Activity & Detailed Earnings Play Strategies - beatles.ru
Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Multi Factor Analysis Ranks Avadel Pharmaceuticals plc as Strong BuyDividend Hike & Stepwise Trade Signal Implementation - beatles.ru
Avadel chief commercial officer resigns, stock down 14% - MSN
Will Avadel Pharmaceuticals plc continue its uptrendStop Loss & Free Weekly Watchlist of Top Performers - Newser
Is Avadel Pharmaceuticals plc a candidate for recovery playJuly 2025 EndofMonth & Reliable Volume Spike Trade Alerts - Newser
Insider Stock Buying Reaches US$761.7k On Avadel Pharmaceuticals - 富途牛牛
Caption Management LLC Buys 104,910 Shares of Avadel Pharmaceuticals PLC. $AVDL - MarketBeat
Smart tools for monitoring Avadel Pharmaceuticals plc’s price actionQuarterly Trade Review & Weekly Market Pulse Updates - Newser
Is a relief rally coming for Avadel Pharmaceuticals plc holdersCEO Change & Daily Profit Maximizing Tips - Newser
Will Avadel Pharmaceuticals plc benefit from macro trendsPortfolio Update Report & Advanced Swing Trade Entry Alerts - Newser
Avadel Pharmaceuticals at Wells Fargo Conference: Strategic Growth and Challenges - Investing.com UK
Avadel Pharmaceuticals Presents 17 Abstracts on LUMRYZ Efficacy at World Sleep 2025, Highlighting Benefits of Once-Nightly Sodium Oxybate for Narcolepsy Treatment - Quiver Quantitative
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025 - The Manila Times
Avadel to Present LUMRYZ Narcolepsy Data at World Sleep 2025 | AVDL Stock News - Stock Titan
Predicting Avadel Pharmaceuticals plc trend using moving averagesJuly 2025 Sector Moves & Real-Time Market Sentiment Alerts - Newser
Avadel Pharmaceuticals stock price target raised to $36 at H.C. Wainwright - Investing.com UK
Is Avadel Pharmaceuticals plc stock ready for a breakout2025 Market Outlook & Reliable Breakout Forecasts - Newser
Applying Elliott Wave Theory to Avadel Pharmaceuticals plcJobs Report & High Accuracy Swing Entry Alerts - Newser
Tick level data insight on Avadel Pharmaceuticals plc volatilityWeekly Volume Report & Daily Price Action Insights - Newser
Published on: 2025-09-04 22:28:10 - Newser
The Once-Nightly, Salt-Free, Artificial Sweetener-Free Oxybate in the Works for Narcolepsy, IH - Sleep Review
Avadel licenses once-at-bedtime oxybate therapy from XWPharma - Investing.com India
Avadel Pharmaceuticals plc Testing Reversal Zone on Weekly ChartDividend Hike & Free Fast Entry Momentum Trade Alerts - beatles.ru
Avadel Pharmaceuticals (AVDL) Attracts Institutional Investment - MSN
Why Avadel Pharmaceuticals plc is moving todayJuly 2025 Technicals & AI Powered Buy/Sell Recommendations - Newser
Avadel licenses once-at-bedtime oxybate therapy from XWPharma By Investing.com - Investing.com Australia
Avadel secures rights to develop valiloxybate globally - Yahoo Finance
Sleep Disorder Market Heats Up with Avadel’s Global Grab for Valiloxybate - geneonline.com
Will Avadel Pharmaceuticals plc rebound enough to break evenJuly 2025 PostEarnings & Free AI Powered Buy and Sell Recommendations - Newser
Can you recover from losses in Avadel Pharmaceuticals plcWeekly Loss Report & Low Drawdown Investment Ideas - Newser
How to read the order book for Avadel Pharmaceuticals plcTrade Risk Report & Weekly Sector Rotation Insights - Newser
Finanzdaten der Avadel Pharmaceuticals Plc-Aktie (AVDL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Avadel Pharmaceuticals Plc-Aktie (AVDL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Thornton Peter J. | Director |
Jan 13 '25 |
Buy |
8.04 |
10,000 |
80,450 |
104,055 |
| Ende Eric J | Director |
Jan 13 '25 |
Buy |
7.84 |
30,000 |
235,218 |
208,900 |
| MCHUGH THOMAS S | Chief Financial Officer |
Dec 13 '24 |
Buy |
10.44 |
2,300 |
24,019 |
87,800 |
| MCHUGH THOMAS S | Chief Financial Officer |
Dec 11 '24 |
Buy |
10.49 |
5,000 |
52,432 |
85,500 |
| Divis Gregory J | Chief Executive Officer |
Dec 06 '24 |
Buy |
9.98 |
9,598 |
95,759 |
9,598 |
| Divis Gregory J | Chief Executive Officer |
Dec 09 '24 |
Buy |
9.82 |
402 |
3,948 |
10,000 |
| Glass Geoffrey Michael | Director |
Dec 10 '24 |
Buy |
9.84 |
20,279 |
199,641 |
75,904 |
| Palczuk Linda | Director |
Dec 06 '24 |
Buy |
10.19 |
3,000 |
30,568 |
66,400 |
2.67%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):